Ampersand Capital Partners, based in Wellesley, Massachusetts, announced its acquisition of Julius Clinical Research. According to data captured in the LevinPro HC database, this acquisition is the 40th contract research organization (CRO) transaction of the year.
Based in the Netherlands, Julius Clinical Research is a leading academic clinical CRO that provides clinical trial services and real-world evidence studies to biopharma sponsors.
Founded in 1988, Ampersand is a middle-market private equity firm with more than $3 billion of assets under management dedicated to investments in the healthcare sector.
This transaction will allow Julius Clinical Research to expand its scientific and therapeutic expertise as well as build its geographic footprint in Europe and North America. The financial terms were not disclosed.
